SCHEMBL647859

SCHEMBL647859

CCCCSc1ccc(O)c2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 6/20 0.46
▸ IDO1 P14902 6/20 0.45
▸ EP300 Q09472 3/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ MAPT P10636 2/20 0.42
▸ NPSR1 Q6W5P4 2/20 0.42
▸ TLR8 Q9NR97 1/20 0.41
▸ EPHX2 P34913 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ KAT2B Q92831 2/20 0.37
▸ KAT8 Q9H7Z6 2/20 0.37
▸ HDAC3 O15379 1/20 0.37
▸ NCOR2 Q9Y618 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ CNR2 P34972 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16664180 0.95 PTGS2 (0.47) PTGS2IDO1EP300ALDH1A1MAPT
SCHEMBL19245741 0.93 PTGS2 (0.48) PTGS2IDO1EP300EPHX2
SCHEMBL9400369 0.93 PTGS2 (0.48) PTGS2IDO1EP300EPHX2
SCHEMBL25738394 0.85 IDO1 (0.43) PTGS2IDO1EP300KAT2BKAT8
SCHEMBL1057913 0.82 IDO1 (0.52) IDO1EP300KAT2BKAT8HDAC3
SCHEMBL25934912 0.81 IDO1 (0.43) IDO1EP300KAT2BKAT8HDAC3
SCHEMBL348041 0.81 PTGS2 (0.50) PTGS2ALDH1A1MAPTNPSR1TLR8
SCHEMBL19245462 0.81 PTGS2 (0.43) PTGS2IDO1EP300MAPTNPSR1
SCHEMBL16519472 0.78 PTGS2 (0.51) PTGS2ALDH1A1MAPTNPSR1TLR8
SCHEMBL9323113 0.78 EPHX2 (0.56) PTGS2ALDH1A1MAPTNPSR1TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160349619-A1 PATTERN FORMING METHOD, RESIST COMPOSITION FOR MULTIPLE DEVELOPMENT USED IN THE PATTERN FORMING METHOD, DEVELOPER FOR NEGATIVE DEVELOPMENT USED IN THE PATTERN FORMING METHOD, AND RINSING SOLUTION FOR NEGATIVE DEVELOPMENT USED IN THE PATTERN FORMING METHOD FUJIFILM CORPORATION (JP) 2016-12-01 — — US disclosed
EP-1580598-B1 Positive resist composition for immersion exposure and pattern-forming method using the same FUJIFILM CORP (JP) 2016-10-12 — — EP disclosed
US-9405197-B2 Pattern forming method, method for manufacturing electronic device, and electronic device FUJIFILM CORPORATION (JP) 2016-08-02 — — US disclosed
US-9291904-B2 Pattern forming method, resist composition for multiple development used in the pattern forming method, developer for negative development used in the pattern forming method, and rinsing solution for negative development used in the pattern forming method FUJIFILM CORPORATION (JP) 2016-03-22 — — US disclosed
US-9250530-B2 — — 2016-02-02 — — US disclosed
EP-1536285-B1 Photosensitive composition, compound for use in the photosensitive composition, and pattern forming method using the photosensitive composition FUJIFILM CORP (JP) 2016-01-06 — — EP disclosed
US-20150160559-A1 PATTERN FORMING METHOD, METHOD FOR MANUFACTURING ELECTRONIC DEVICE, AND ELECTRONIC DEVICE FUJIFILM CORPORATION (JP) 2015-06-11 — — US disclosed
US-9023576-B2 Positive resist composition for immersion exposure and pattern-forming method using the same FUJIFILM CORPORATION (JP) 2015-05-05 — — US disclosed
US-20150079522-A1 PATTERN FORMING METHOD, RESIST COMPOSITION FOR MULTIPLE DEVELOPMENT USED IN THE PATTERN FORMING METHOD, DEVELOPER FOR NEGATIVE DEVELOPMENT USED IN THE PATTERN FORMING METHOD, AND RINSING SOLUTION FOR NEGATIVE DEVELOPMENT USED IN THE PATTERN FORMING METHOD FUJIFILM CORPORATION (JP) 2015-03-19 — — US disclosed
US-8951718-B2 Pattern forming method, resist composition for multiple development used in the pattern forming method, developer for negative development used in the pattern forming method, and rinsing solution for negative development used in the pattern forming method FUJIFILM CORPORATION (JP) 2015-02-10 — — US disclosed
US-8119778-B2 Reversibly thermochromic compositions BASF SE (DE) 2012-02-21 — — US disclosed
EP-2032370-B1 REVERSIBLY THERMOCHROMIC COMPOSITIONS BASF SE (DE) 2010-11-10 — — EP disclosed
US-20100234494-A1 Reversibly thermochromic compositions CIBA CORPORATION 2010-09-16 — — US disclosed
EP-2032370-A2 REVERSIBLY THERMOCHROMIC COMPOSITIONS Ciba Holding Inc. (CH) 2009-03-11 — — EP disclosed
WO-2007147843-A2 REVERSIBLY THERMOCHROMIC COMPOSITIONS CIBA HOLDING INC. (CH) 2007-12-27 — — WO disclosed
US-7273690-B2 Positive resist composition for immersion exposure and method of pattern formation with the same FUJIFILM CORPORATION (JP) 2007-09-25 — — US disclosed
US-20070218405-A1 Positive resist composition and pattern formation method using the positive resist composition FUJIFILM CORPORATION (JP) 2007-09-20 — — US disclosed
EP-1835343-A1 Positive resist composition and pattern formation method using the positive resist composition FUJIFILM Corporation (JP) 2007-09-19 — — EP disclosed
EP-1835340-A1 Positive resist composition and pattern formation method using the positive resist composition FUJIFILM Corporation (JP) 2007-09-19 — — EP disclosed
US-20070105045-A1 Positive resist composition and pattern formation method using the positive resist composition FUJIFILM CORPORATION 2007-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234494-A1 Reversibly thermochromic compositions CRY1, REL, CRY2 PTGS2 1468/4885IDO1 936/4885EP300 1108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback